Our COVID Vaccine Statement and other related resources for patients and our researchers and research staff are available on the COVID-19 Updates webpage.
Deb Barton PhD RN
Symptom Management [CC]
Measure the ability of two dose levels of bupropion, 150 or 300 mg of extended release, to improve sexual desire more than a placebo at 9 weeks (8 weeks on the target dose) as measured by the desire subscale of the FSFI.
Patients with diagnosis of breast or gynecologic cancer (ovarian, endometrial, vulvar, cervical, and vaginal), with a score of <9 on the PHQ-F and a FSFI desire subscale baseline score that is less than 3.3.
Available via the National Cancer Institute (NCI) Cancer Trials Support Unit (CTSU) website.
6/19/2019 - NRG-CC004 Webinar
Webinar Recording Webinar Slides
We are a leading protocol organizations within the National Clinical Trials Network and we seek to improve the lives of cancer patients by conducting practice-changing, multi-institutional clinical and translational research. Learn More
NRG Oncology Foundation, Inc, is a nonprofit, tax-exempt foundation. Donations to NRG Oncology help us conduct this important mission, and are tax-deductible to the extent permitted by law.